Forced switch, economic slowdown?
This article was originally published in The Tan Sheet
Executive Summary
FDA will "negatively impact employee health, workplace productivity, consumer costs and the patient-physician relationship" if it forces the Rx-to-OTC switch of low- and non-sedating antihistamines Allegra (Aventis), Zyrtec (Pfizer) and Clarinex (Schering-Plough) in accordance with citizen petitions submitted by WellPoint Health Networks in 1998 and 2002, the Institute for Health and Productivity Management says in Aug. 1 comments. "The domino effect from an OTC shift is simple: a lower quality of life and increased out-of-pocket costs for employees would lead to lost productivity for employers because workers either forgo medication or use cheaper sedating products that interfere with job safety and performance," IHPM states. In the U.S., 3.4 mil. workdays and $150 mil. in wages already are lost each year due to allergies, IHPM contends, citing estimates from a 1999 American Journal of Managed Care study...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.